ICAD
vs
S&P 500
ICAD
S&P 500
Over the past 12 months, ICAD has outperformed S&P 500, delivering a return of +17% compared to the S&P 500's +12% growth.
Stocks Performance
ICAD vs S&P 500
Performance Gap
ICAD vs S&P 500
Performance By Year
ICAD vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
ICAD Inc
Glance View
iCAD, Inc. is a medical technology company, which engages in the provision cancer detection and therapy solutions. The company is headquartered in Nashua, New Hampshire and currently employs 136 full-time employees. The firm operates through two segments: Cancer Detection (Detection) and Cancer Therapy (Therapy). In the Detection segment, the Company’s solutions include advanced image analysis and workflow solutions enables healthcare professionals to serve patients by identifying pathologies and pinpointing the prevalent cancers earlier, and a comprehensive range of artificial intelligence and computer aided detection (CAD) systems and workflow solutions for two-dimension(2D) and third dimension (3D) mammography, magnetic resonance imaging (MRI) and computed tomography (CT). In the Therapy segment, the Company offers the Xoft System, an isotope-free cancer treatment platform technology. The Xoft System can be used for the treatment of early-stage breast cancer, endometrial cancer, cervical cancer and nonmelanoma skin cancer.
